摘要
目的:对莫西沙星序贯疗法治疗社区获得性肺炎进行临床疗效观察及药物经济学分析评价。方法:运用随机、平行、开放的研究方法试验组莫西沙星400mg,qd静脉给药后口服莫西沙星400mg,qd序贯治疗方案),和对照,(,组(头孢呋辛3.0g/次,q12h,并联合阿奇霉素500mg,qd静脉给药后,口服头孢克洛片375mg/次,bid,及阿奇霉素500mg,qd),观察两组的临床疗效、住院时间安全性并进行成本-效果分析。结果:试验组与对照组的临床疗效无显,,著性差异但成本-效果分析表明试验组优于对照组。结论:对于因社区获得性肺炎住院治疗的患者莫西沙星单药序,,贯治疗优于标准的联合用药方案。
Objective： To evaluate the clinical consequences and cost- effective from perspective of sequential from intravenous infusion to orally Moxifloxacin in patients with community-acquired pneumonia. Methods： A prospective observational study was assessing that sixty-four patients randomly to treatment with moxifloxacin or cefuroxime sodium plus azithromycin. Moxifloxacin（400 mg,qd） was administrated sequential from intravenous infusion to oral dosing; Cefuroxime sodium （3.0 g, ql2h） and azithromycin （500 mg qd） were administrated synchronization intravenous infusion, then orally by cefaclor tablet（375 rag, bid） and azithromycin tablet（500 mg,qd） . The clinical consequence, time of hospitalization, securitywere observed, and cost-effective was analyzed between two groups. Results： the overall clinical efficacy rate and security are few different, but time of hospitalization and cost-effective of moxifloxacin was advanced of cefuroxime sodium plus azithromycin. Conclusion： Sequential therapy of moxifloxacin is advanced of clinical criteria treatment of cefuroxime sodium plus azithromycin in treating patients with community-acquired pneumonia.
出处
《抗感染药学》
2006年第3期139-142,共4页
Anti-infection Pharmacy
关键词
莫西沙星
序贯疗法
社区获得性肺炎
成本-效果分析
Moxifloxacin
sequential treatment
community-acquired pneumonia
cost-effective analyse
